Do analysts recommend AYTU or JATT?

Aytu BioPharma presently has a consensus target price of $10.75, suggesting a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, AYTU or JATT?

JATT Acquisition has lower revenue, but higher earnings than Aytu BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Do analysts rate AYTU or ?

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, AYTU or ?

has lower revenue, but higher earnings than Aytu BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A N/A N/A N/A N/A N/A

Is AYTU or more profitable?

has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. 's return on equity of 0.00% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% N/A N/A N/A

Which has better earnings & valuation, AYTU or BTMD?

biote has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A biote $188.16M 0.46 $27.05M $0.44 5.18

Is AYTU or BTMD more profitable?

biote has a net margin of 8.29% compared to Aytu BioPharma's net margin of -60.17%. biote's return on equity of -25.72% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% biote 8.29% -25.72% 15.12%

Aytu BioPharma (AYTU) Competitors

$2.16 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.12 -0.04 (-2.08%)

As of 07/24/2026 07:34 PM Eastern

Compare

AYTU vs. CRDF, JATT, LONA, CGTX, and BTMD

Should you buy Aytu BioPharma stock or one of its competitors? MarketBeat compares Aytu BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aytu BioPharma include Cardiff Oncology (CRDF), JATT Acquisition (JATT), Athira Pharma (LONA), Cognition Therapeutics (CGTX), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Aytu BioPharma compare to Cardiff Oncology?

Aytu BioPharma (NASDAQ:AYTU) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Cardiff Oncology's average media sentiment score of 1.87 beat Aytu BioPharma's score of -0.37 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Cardiff Oncology	Very Positive

Aytu BioPharma has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Cardiff Oncology	$525K	107.89	-$45.85M	-$0.67	N/A

Aytu BioPharma has a net margin of -60.17% compared to Cardiff Oncology's net margin of -8,527.43%. Aytu BioPharma's return on equity of -69.93% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 397.69%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 807.00%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Aytu BioPharma and Cardiff Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to JATT Acquisition?

Aytu BioPharma (NASDAQ:AYTU) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. JATT Acquisition's return on equity of -49.58% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
JATT Acquisition	N/A	-49.58%	2.84%

JATT Acquisition has lower revenue, but higher earnings than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. JATT Acquisition's average media sentiment score of 0.00 beat Aytu BioPharma's score of -0.37 indicating that JATT Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
JATT Acquisition	Neutral

Aytu BioPharma presently has a consensus target price of $10.75, suggesting a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

JATT Acquisition beats Aytu BioPharma on 7 of the 11 factors compared between the two stocks.

How does Aytu BioPharma compare to ?

Aytu BioPharma (NASDAQ:AYTU) and (:) are related companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

has lower revenue, but higher earnings than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
	N/A	N/A	N/A	N/A	N/A

has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. 's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
	N/A	N/A	N/A

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, had 1157 more articles in the media than Aytu BioPharma. MarketBeat recorded 1158 mentions for and 1 mentions for Aytu BioPharma. 's average media sentiment score of 0.00 beat Aytu BioPharma's score of -0.37 indicating that is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
	Neutral

Summary

Aytu BioPharma beats on 6 of the 11 factors compared between the two stocks.

How does Aytu BioPharma compare to Cognition Therapeutics?

Aytu BioPharma (NASDAQ:AYTU) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Cognition Therapeutics' average media sentiment score of 1.87 beat Aytu BioPharma's score of -0.37 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Cognition Therapeutics	Very Positive

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aytu BioPharma presently has a consensus price target of $10.75, indicating a potential upside of 397.69%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 262.52%. Given Aytu BioPharma's higher possible upside, equities research analysts clearly believe Aytu BioPharma is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aytu BioPharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Cognition Therapeutics beats Aytu BioPharma on 8 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to biote?

Aytu BioPharma (NASDAQ:AYTU) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Aytu BioPharma has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, biote has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

biote has a net margin of 8.29% compared to Aytu BioPharma's net margin of -60.17%. biote's return on equity of -25.72% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
biote	8.29%	-25.72%	15.12%

biote has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
biote	$188.16M	0.46	$27.05M	$0.44	5.18

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aytu BioPharma presently has a consensus target price of $10.75, indicating a potential upside of 397.69%. biote has a consensus target price of $2.75, indicating a potential upside of 20.61%. Given Aytu BioPharma's higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, biote had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for biote and 1 mentions for Aytu BioPharma. biote's average media sentiment score of 0.94 beat Aytu BioPharma's score of -0.37 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
biote	Positive

Summary

biote beats Aytu BioPharma on 14 of the 17 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.18M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.47	21.48	27.14	23.64
Price / Sales	0.35	170.08	517.08	89.50
Price / Cash	5.75	157.90	50.54	59.64
Price / Book	1.02	7.88	10.28	6.07
Net Income	-$13.56M	$23.86M	$3.60B	$331.99M
7 Day Performance	0.47%	-3.82%	-1.27%	-0.63%
1 Month Performance	-0.46%	-2.61%	-0.37%	-2.00%
1 Year Performance	-17.87%	32.79%	18.30%	13.62%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.0449 of 5 stars	$2.16 flat	$10.75 +397.7%	-18.5%	$23.18M	$66.38M	N/A	160	Negative News
CRDF Cardiff Oncology	4.0696 of 5 stars	$1.31 -3.0%	$7.50 +472.5%	-80.0%	$92.30M	$590K	N/A	20	Positive News Analyst Downgrade
JATT JATT Acquisition	N/A	$10.76 -6.4%	N/A	+573.2%	$92.29M	N/A	N/A	3	News Coverage Gap Down
LONA Athira Pharma	3.5525 of 5 stars	$9.44 +8.8%	$15.00 +59.0%	N/A	$91.68M	N/A	N/A	40	Gap Up
CGTX Cognition Therapeutics	2.2898 of 5 stars	$1.01 -1.0%	$3.33 +230.0%	+6.7%	$91.29M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. CRDF, JATT, LONA, CGTX, and BTMD

How does Aytu BioPharma compare to Cardiff Oncology?

Summary

How does Aytu BioPharma compare to JATT Acquisition?

Summary

How does Aytu BioPharma compare to ?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Summary

How does Aytu BioPharma compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. CRDF, JATT, LONA, CGTX, and BTMD

How does Aytu BioPharma compare to Cardiff Oncology?

Which has more risk and volatility, AYTU or CRDF?

Does the media prefer AYTU or CRDF?

Which has preferable valuation and earnings, AYTU or CRDF?

Is AYTU or CRDF more profitable?

Do analysts recommend AYTU or CRDF?

Do insiders and institutionals hold more shares of AYTU or CRDF?

Summary

How does Aytu BioPharma compare to JATT Acquisition?

Do insiders and institutionals have more ownership in AYTU or JATT?

Is AYTU or JATT more profitable?

Which has higher earnings & valuation, AYTU or JATT?

Does the media refer more to AYTU or JATT?

Do analysts recommend AYTU or JATT?

Summary

How does Aytu BioPharma compare to ?

Which has higher earnings and valuation, AYTU or ?

Is AYTU or more profitable?

Do analysts rate AYTU or ?

Do insiders & institutionals have more ownership in AYTU or ?

Does the media refer more to AYTU or ?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Does the media prefer AYTU or CGTX?

Which has more volatility & risk, AYTU or CGTX?

Do institutionals & insiders believe in AYTU or CGTX?

Do analysts recommend AYTU or CGTX?

Which has stronger earnings and valuation, AYTU or CGTX?

Is AYTU or CGTX more profitable?

Summary

How does Aytu BioPharma compare to biote?

Which has more volatility and risk, AYTU or BTMD?

Is AYTU or BTMD more profitable?

Which has better earnings & valuation, AYTU or BTMD?

Do insiders & institutionals believe in AYTU or BTMD?

Do analysts prefer AYTU or BTMD?

Does the media prefer AYTU or BTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools